|
Exosomal Drug Delivery
|
5R44CA221487-02
|
$1,000,000
|
|
SPENCER, WENDY
|
3P BIOTECHNOLOGIES, INC.
|
|
Compact Navigation System for CT-guided Needle Interventions
|
1UT1CA224886-01A1
|
$149,927
|
|
TSE, TSZ HO
|
3T TECHNOLOGIES, LLC
|
|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
2R42CA203456-02A1
|
$999,501
|
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
|
1R44CA224718-01A1
|
$159,365
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
5R44CA162629-03
|
$833,374
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
5R44CA221539-02
|
$660,235
|
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
Affinity Purification of Biologics with Mimetope Peptides
|
1R43CA228945-01
|
$217,898
|
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Personalized precision dosing of biologic therapies in oncology
|
5R44CA217336-02
|
$720,363
|
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S1
|
$50,000
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
Image-guided ultrasound ablation for precision targeting of prostate cancer
|
1R01CA230323-01
|
$580,217
|
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Fluorescent Nanodiamonds for Multiplexed Imaging and Diagnostics
|
1R43CA232901-01
|
$291,083
|
|
SHENDEROVA, OLGA
|
ADAMAS NANOTECHNOLOGIES, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
Training African Pathologists in Cancer Diagnosis
|
1R13CA232439-01
|
$38,120
|
|
WILSON, MICHAEL
|
AFRICAN STRATEGIES /ADVANCING PATHOLOGY
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Womens Interagency HIV Study (WIHS-V)
|
3U01AI035004-25S1
|
$144,370
|
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Genetic and Dietary Interactions in MMR Deficient Colon Tumorigenesis
|
1R01CA222358-01A1
|
$635,306
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Nutritionally Driven Sporadic Intestinal Tumors: Impact on Stem Cells
|
1R01CA229216-01
|
$493,238
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Building Research Capacity to Address the Challenge of Non Communicable Diseases and Injuries in Rwanda The GUKORANA Research Center
|
5P20CA210284-02
|
$247,982
|
|
CASTLE, PHILIP
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Synergistic co-targeting of pro-apoptotic BAX and anti-apoptotic BCL-XL in cancer
|
1F31CA236434-01
|
$44,524
|
|
LOPEZ-ARROYO, ANDREA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ
|
5R01CA218429-02
|
$1,347,851
|
|
ROHAN, THOMAS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Methylome characterization of bronchial epithelial projenitor cells
|
5R21CA209436-02
|
$180,130
|
|
SPIVACK, SIMON
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Next Generation of HPV and Cervical Cancer Research in HIV+ Women
|
1R01CA230331-01
|
$670,295
|
|
STRICKLER, HOWARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Identification and targeting of pathways separating healthy stem cell aging from malignant transformation
|
1R01CA230756-01
|
$382,013
|
|
WILL, BRITTA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues
|
1R43CA236097-01
|
$300,000
|
|
LIM, MARK
|
AMBERGEN, INC
|
|
11th AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
|
1R13CA236113-01
|
$74,000
|
|
FOTI, MARGARET
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Integrative Molecular Epidemiology Workshop
|
2R25CA174664-06
|
$258,400
|
|
SELLERS, THOMAS
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Molecular, cancer-specific, intraoperative imaging of breast surgical margin assessment
|
1R41CA221595-01A1
|
$300,000
|
|
SHIH, WEI-HENG
|
AQD LIFE SCIENCES, LLC
|
|
Developing a mobile application for circadian wellness in cancer patients
|
1R43CA236557-01A1
|
$221,237
|
|
WALCH, OLIVIA
|
ARCASCOPE, LLC
|
|
Validation and Advanced Development of Albumin Oxidizability as a Marker of Plasma/Serum Integrity
|
1R33CA217702-01A1
|
$364,966
|
|
BORGES, CHAD
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
3R01CA201179-03S1
|
$227,376
|
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors
|
3R01CA182901-04S1
|
$39,254
|
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Therapeutic peptide for hepatocellular carcinoma
|
1R43CA232947-01
|
$299,983
|
|
PANDEY, NIRANJAN
|
ASCLEPIX THERAPEUTICS, LLC
|
|
Create three-member project team to refine commercialization plans for AML-Mutation Counter, a tool to detect residual and recurrent leukemia.
|
3R41CA213690-01S1
|
|
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
Proteasome inhibitors for the treatment of solid tumors
|
5R01CA213223-02
|
$356,014
|
|
KISSELEV, ALEXEI
|
AUBURN UNIVERSITY AT AUBURN
|
|
Novel Biomarkers for the Clinical Management of Bladder Cancer
|
1R01CA227277-01A1
|
$466,211
|
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
P53-dependent immunogenic DCs in the tumor microenvironment
|
1R50CA232983-01
|
$203,853
|
|
SHARMA, MADHAV
|
AUGUSTA UNIVERSITY
|
|
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer
|
1R44CA232963-01
|
$299,937
|
|
GLODE, MIKE
|
AURORA ONCOLOGY, INC.
|
|
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
|
1R44CA233143-01
|
$218,588
|
|
LAMPI HERMANSON, DAVID
|
B-MOGEN BIOTECHNOLOGIES, INC.
|
|
Integrative Oncology: From Research to Practical Applications
|
1R13CA236121-01
|
$5,000
|
|
RAO, SANTOSH
|
BANNER HEALTH
|
|
Improving pathologic nodal staging of resected lung cancer
|
2R01CA172253-06
|
$499,347
|
|
OSAROGIAGBON, RAYMOND
|
BAPTIST MEMORIAL HOSPITAL - TIPTON
|
|
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
5R01CA181275-05
|
$307,736
|
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
A CD47-blocking oncolytic vaccinia virus for cancer therapy
|
5F30CA203270-03
|
$44,524
|
|
CAO, FELICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
ALTERED MICROBIOME IN PANCREATITIS, DIABETES AND PANCREATIC CANCER
|
5U01DK108326-04
|
$190,000
|
|
FISHER, WILLIAM
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis
|
1R01CA230848-01
|
$442,560
|
|
FU, LONING
|
BAYLOR COLLEGE OF MEDICINE
|
|
The role of DNMT3A in gene regulation and stem cell expansion
|
5F99CA222736-02
|
$44,524
|
|
HUANG, YUNG-HSIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mitochondrial DNA copy number and fat metabolism in triple negative breast cancer
|
5R03CA212816-02
|
$79,250
|
|
KAIPPARETTU, BENNY
|
BAYLOR COLLEGE OF MEDICINE
|
Total relevant funding to Pituitary for this search: $2,158,314
|